The Pharma Data

JANUARY 18, 2021

“There are no approved therapies for epilepsy caused by SLC13A5 that address the underlying cause of this disease,” said RA Session II, President, Founder and CEO of Taysha. “We We are pleased that the FDA recognizes TSHA-105’s potential as an innovative therapeutic option for SLC13A5 deficiency,” said Rachel Bailey, Ph.D.,

Therapies 52

Therapies Disease Treatment FDA 52

The Pharma Data

MARCH 31, 2023

However, the disease is largely managed with treatments approved for adults, based on data from adult studies,” said David Soergel, M.D., This would support extension of the regulatory data protection to November 2026. Novartis established the largest global clinical program in the HF disease area across the pharma industry to date.

Hospitals 75

Hospitals Trials Treatment Clinical Trials 75

Drug Target Review

JANUARY 4, 2024

The highly promising programs we have in the pipeline are for two diseases with unmet medical need — Retinitis Pigmentosa (RP) and chronic heart disease. Well, unfortunately, most available treatments for degenerative eye conditions and chronic heart disease treat only the symptoms. This is a huge and critical difference.

Therapies 98

Therapies Small Molecule Production Disease 98

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. In the UK, six universities received £4.25 In the UK, six universities received £4.25

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Drug Discovery World

FEBRUARY 2, 2024

He says: “Then, maybe in 2025/2026, we’re ready to apply vast and dramatic AI models, because then we’ll have it.” Recently, the very first human in vivo CRISPR therapeutic was approved in the EU for sickle cell disease, by Vertex and by CRISPR Therapeutics.

Compliance 130

Compliance Science Pharma Companies Engineering 130

The Pharma Data

MARCH 31, 2022

million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026.

Government 52

Government Treatment Vaccine Disease 52

The Pharma Data

OCTOBER 31, 2020

Kuo-Lung Huang , the Chairman and CEO of TaiGen notes, “Influenza is a life threatening disease with significant unmet medical needs and high medical burden. billion USD by 2026 at a CAGR of 11.5%. billion USD by 2026 at a CAGR of 11.5%. in the near future.” billion USD in 2019 and is estimated to reach 5.03

FDA Approval 52

FDA Approval FDA Virus Clinical Development 52

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

RNA 52

RNA Pharmaceuticals Production Disease 52

The Pharma Data

APRIL 14, 2021

The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed. Sanofi offers a portfolio of vaccines to protect children, adolescents, and adults from diseases such as influenza, infectious diseases, and endemic diseases.

Vaccine 52

Vaccine Production Disease International 52

National Institute on Drug Abuse: Nora's Blog

DECEMBER 14, 2022

according to provisional data from the Centers for Disease Control and Prevention. There are many other health consequences of addiction, including the transmission of infectious diseases like HIV and hepatitis C. Other consequences of drug use, such as infectious disease transmission, must also be mitigated.

Research 52

Research Treatment Disease Drugs 52

Drug Target Review

JULY 4, 2023

The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . billion, compared to $19.9 Tuyen Ong, MD, CEO, Ring Therapeutics. .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

MAY 15, 2023

Work is set to begin this year, with full operations provisionally planned for late 2026. In addition, Sandoz recently signed a Memorandum of Understanding to build a new biologics production plant in Slovenia – an expected investment of at least USD 400 million to support increasing global demand for biosimilar medicines.

Biosimilars 40

Biosimilars Production Government Clinical Trials 40

The Pharma Data

APRIL 15, 2022

New GSK reaffirms its full-year 2022 guidance, the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**, and long-term sales ambition. Patients were symptomatic and anaemic and had been previously treated with an FDA-approved JAK inhibitor. GSK is a science-led global healthcare company.

FDA Approval 52

FDA Approval Treatment Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 23, 2024

Voyager Therapeutics has announced new data from its two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease. Based on these data, Voyager has advanced this programme into late research and expects to file an investigational new drug (IND) application in 2026.

Therapies 130

Therapies Pharmacokinetics RNA International 130

The Pharma Data

NOVEMBER 11, 2020

. Strategic alliance with Novo Nordisk to develop novel therapies for kidney diseases. Access to QUOD biobank to expand patient database into liver disease. Expanded collaboration with Centogene into Gaucher disease. CORPORATE. GUIDANCE FOR FULL-YEAR 2020 CONFIRMED.

Disease 40

Disease Production Drugs Pharmaceuticals 40

Drug Discovery World

JANUARY 24, 2024

PW: The big challenge with fibrotic diseases is that they evolve slowly and are diagnosed late in the disease process. Only a few drugs have received approval for fibrotic diseases like IPF (idiopathic pulmonary fibrosis). The most crucial step in this process is the selection of the relevant disease markers.

Small Molecule 147

Small Molecule Research Pharma Companies Disease 147

The Pharma Data

DECEMBER 12, 2020

Dedicated rare disease unit to be headquartered in Boston. Pascal Soriot , Chief Executive Officer, AstraZeneca , said: “ Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology.

Regulations 75

Regulations International Disease Small Molecule 75

Agency IQ

MAY 17, 2024

The Creating Hope Reauthorization Act would reauthorize the FDA’s Rare Pediatric Disease Priority Review Voucher program. The markup hearing comes three months after the E&C Committee last held a hearing on 18 bills related to rare diseases, including all four of the above-mentioned bills. DORIS MATSUI (D-Calif.)

FDA 40

FDA Disease FDA Approval Production 40

Drug Discovery World

NOVEMBER 14, 2022

billion by 2026, at a compound annual growth rate (CAGR) of 28.4% during the forecast period of 2021-2026. Replay separates technology development from therapeutic product development within disease area-specific product companies. billion in 2021 to $33.2 This highlights its potential and underlines its appeal to investors. .

DNA 130

DNA Drugs Engineering Production 130

Drug Discovery World

OCTOBER 13, 2022

Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets, including infectious diseases and cancers. mRNA presents versatility plus flexibility to target a broader range of diseases. . billion by 2026 9. CDMOs adapting fast .

Vaccine 130

Vaccine Therapies Drugs RNA 130

Drug Discovery World

FEBRUARY 26, 2024

Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas. She and bit.bio are going beyond this cell type and looking at producing other cell types which may provide answers to a range of diseases beyond blood cancers.

Therapies 130

Therapies Treatment Engineering Disease 130

The Pharma Data

JUNE 2, 2022

Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and milder diseases such as sinusitis and otitis media and remains a significant unmet medical need despite the availability of current pneumococcal vaccines. .” pneumoniae invasive disease and pneumonia in adults 50 years and above.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and milder diseases such as sinusitis and otitis media and remains a significant unmet medical need despite the availability of current pneumococcal vaccines. pneumoniae invasive disease and pneumonia in adults 50 years and above. Pneumococcal disease.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

APRIL 29, 2022

The site, scheduled for completion in 2026, will be in close proximity to several major academic, pharma and biotech institutions, inspiring greater collaboration and innovation potential, and providing access to future talent.

Science 40

Science International Disease 40

The Pharma Data

JANUARY 25, 2021

The Company may not redeem the notes prior to February 6, 2026. BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. The initial conversion price of the notes represents a premium of approximately 47.5%

Marketing 52

Marketing Disease Clinical Trials Production 52

The Pharma Data

NOVEMBER 11, 2020

About Sequana Medical Sequana Medical is a commercial stage medical device company developing the alfa pump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. and EU5 by 2026. GHENT, Belgium, Nov.

Therapies 40

Therapies Marketing Disease Clinical Research 40

The Pharma Data

DECEMBER 16, 2020

About Sequana Medical Sequana Medical is a commercial stage medical device company developing the alfa pump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. and EU5 by 2026. GHENT, Belgium, Dec.

Therapies 40

Therapies Marketing Disease Clinical Research 40

Agency IQ

FEBRUARY 15, 2024

If you’re looking for something specific, we recommend using the search function in your browser (Ctrl-F) to look for keywords of interest.

FDA 40

FDA Science Biosimilars Production 40

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. However, 95% of the over 6,000 recognized orphan diseases still have no treatment options. member states. no available treatment.

Marketing 40

Marketing Biosimilars Regulations Drugs 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. Rare Disease. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 23, 2022

There is also evidence that methamphetamine may make the body more vulnerable to HIV acquisition and contribute to HIV disease progression. The disinhibiting effects of methamphetamine can increase certain sexual behaviors that make transmission of HIV more likely.

Treatment 52

Treatment Virus Research Drugs 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV ( Euronext Brussels: SEQUA ) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Michael Felker and Dr. James Udelson as new Heart Failure Scientific Advisors. and EU5 by 2026.

Clinical Trials 40

Clinical Trials Clinical Research Therapies FDA 40

Drug Discovery World

FEBRUARY 22, 2024

Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In With the breadth and range of central nervous system disorders – for example Parkinson’s disease and multiple sclerosis – facing the global population there is an unmet need within this area of drug discovery.

Drugs 147

Drugs Clinical Trials Disease Therapies 147

The Pharma Data

NOVEMBER 18, 2020

Results of preclinical studies demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models published in Journal of Nuclear Medicine. NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. million ).

Trials 40

Trials Clinical Supply Production Therapies 40

Agency IQ

APRIL 8, 2024

The FDA created a parallel tool, called the eSubmitter which worked like the SRP with the caveat that case information was not uploaded to FAERS but to the Vaccine Adverse Event Reporting System (VAERS), a program co-monitored by both the FDA and the Centers for Disease Control and Prevention (CDC). database-to-database submissions).

FDA 40

FDA Production Regulations Vaccine 40

Agency IQ

AUGUST 18, 2023

Otherwise, EUDAMED has been proceeding with finishing testing on the remaining modules in order to complete the minimum viable product (MVP) for the complete database by the end of the year, for a database audit in Q1/Q2 2024 and all modules mandatory to use by Q2 2026. We still need two more implementing acts , on designation of E.U.

Science 40

Science Regulations Laboratories Production 40